Since the inferred biomarkers including SRC, ARNT, TBP, and SNAI2 from the previous analysis were assumed to be influential in the tumorigenesis of serous ovarian tumors, we gathered relevant clinical samples from a cohort of patients (serous BOT, n = 9; serous ovarian carcinoma, n = 41, including n = 8, 2, 23, and 8 for FIGO stages I–IV, respectively) to explore the clinical characteristics and verify the specific manifestations of the four abovementioned selected DEGs that were determined to participate in the pathogenetic mechanisms of serous ovarian tumors. Here, TBP is linked to ovarian serous carcinoma.